CK-102
CK-102 is an interleukin-1 (IL-1) inhibitor. CK-102 reduces mRNA synthesis. CK-102 does not inhibit DNA synthesis. CK-102 only slightly inhibits protein synthesis, or has no effect on it. CK-102 delays wound healing after ophthalmic surgery and prolongs the failure time of trabeculectomy fistulas. CK-102 inhibits lens protein-induced ocular inflammation at both early and late stages. CK-102 inhibits endotoxin-induced uveitis. CK-102 does not inhibit interleukin-1-induced uveitis. CK-102 can be used in research related to glaucoma filtration failure and uveitis.
For research use only. We do not sell to patients.
- CAS No.: 6236-97-1
- Formula: C15H13NO
- Molecular Weight:223.28
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
IL-1 |
In Vitro
CK-102 (10-100 μg/mL; 24-72 h) inhibits proliferation of SIRC rabbit corneal fibroblast cells in a non-cytolytic manner, with viable cell counts remaining at or above initial levels while growing more slowly than controls across 10, 30, and 100 μg/mL concentrations at 24, 48, and 72 h[1].
CK-102 (10-100 μg/mL; 24-72 h) produces limited, inconsistent inhibition of DNA synthesis, transient inhibition of RNA synthesis at 24 and 48 h, and variable effects on protein synthesis (with occasional reduction or increase) in SIRC rabbit corneal fibroblast cells across 10, 30, and 100 μg/mL concentrations at 24, 48, and 72 h[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SIRC rabbit corneal fibroblast cells
-
Concentration:10 μg/mL; 30 μg/mL; 100 μg/mL
-
Incubation Time:24 h; 48 h; 72 h
-
Result:Reduced viable cell numbers compared to controls at each time point.
Inhibited cell proliferation, with growth reduced initially but recovering later and proceeding at a slower rate than controls.
Maintained viable cell counts at or above the starting cell count, confirming no cytolytic effect.
In Vivo
CK-102 (1%; topical; single instillation; 1 hour prior to lens protein challenge) significantly suppresses both early and late phases of lens protein-induced uveitis in Oryctolagus cuniculus, with comparable efficacy to Prednisolone (HY-17463)[3].
CK-102 (10 mg/kg; i.p.; three times daily) significantly suppresses endotoxin-induced uveitis in rats, with greater potency than Prednisolone at an equivalent dose[3].
CK-102 (10 mg/kg; i.p.; three times daily) does not suppress interleukin-1-induced uveitis in rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Dutch Belted (adult, specific pathogen free for Pasteurellosis, glaucoma model via bilateral partial thickness trabeculectomy filtration surgery)[2]
-
Dosage:10 mg
-
Administration:subTenons injection; single dose; immediately after surgery
-
Result:Prolonged the mean number of days to filtration fistula failure by 30% compared to vehicle control, with statistical significance.
Showed no side effects at the tested dose.
-
Animal Model:New Zealand albino rabbits (either sex, 2.0 to 3.0 kg)[3]
-
Dosage:1%
-
Administration:topical; single instillation; 1 hour prior to lens protein challenge
-
Result:Significantly suppressed fluorescein concentration (a marker of inflammation) in the anterior chamber at all measured time points (30, 60, 120, 180, 240, 300, 360 minutes) compared to solvent control, with mean values consistently lower than control.
Suppressed both early (0-3 hour) and late (4-5 hour) phases of inflammation.
-
Animal Model:Sprague-Dawley rats (250-350 grams)[3]
-
Dosage:10 mg/kg
-
Administration:i.p.; three times daily; at 0, 4, and 10 hours after endotoxin injection
-
Result:Significantly suppressed uveitis responses (measured via fluorescein concentration) at 1.5, 2, 3, 4, 5, and 6 hours after fluorescein injection, with mean fluorescein concentrations consistently lower than control.
Observed no obvious side effects during the experiment.
-
Animal Model:Sprague-Dawley rats (250-350 grams)[3]
-
Dosage:10 mg/kg
-
Administration:i.p.; three times daily; at 0, 4, and 10 hours after interleukin-1 injection
-
Result:Did not significantly affect interleukin-1-induced uveitis; fluorescein concentrations in treated rats were not statistically different from control values at any measured time point.
Chemical Information
-
CAS No. 6236-97-1
-
Molecular Weight 223.28
-
Formula C15H13NO
-
SMILES
O=C1C=2C=CC=CC2NC=3C1=CC=C(C3C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell-Exclusion Zone Migration Assay
The Cell-Exclusion Zone (CEZ) migration assay is an in vitro 2D cell migration method in which a defined cell-free area is created using removable physical barriers such as silicone stoppers, allowing cells to be seeded around the barrier and subsequently migrate into the cleared zone after barrier removal. This approach enables quantification of collective cell migration by monitoring repopulation of the initially cell-free region over time using microscopy-based imaging. Compared with scratch-based wound healing assays, barrier-based exclusion methods are designed to avoid mechanical damage to the extracellular matrix and reduce injury-induced effects on boundary cells, thereby improving interpretability of migration behavior in vitro. The assay readout is typically the progressive reduction in the cell-free area or the number of cells invading the exclusion zone, reflecting coordinated cell motility relevant to physiological processes such as wound healing, epithelial repair, and ca
Purity & Documentation
References
[1]. Chen Z, et al. Inhibitory effects of interleukin-1 blockers on corneal fibroblast proliferation. J Ocul Pharmacol Ther. 1996;12(2):169-182. [Content Brief]
[2]. Schwade ND, et al. Effects of interleukin-1 blockers on ophthalmic wound healing in a rabbit model of trabeculectomy. J Ocul Pharmacol Ther. 1995;11(2):125-134. [Content Brief]
[3]. Chiou GC, et al. Prevention and treatment of ocular inflammation with a new class of non-steroidal anti-inflammatory agents. J Ocul Pharmacol. 1994;10(1):335-347. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- CK-102
- 6236-97-1
- CK102
- CK 102
- Interleukin Related
- DNA/RNA Synthesis
- endotoxin-induced uveitis
- interleukin-1
- fibroblast proliferation
- SIRC rabbit corneal fibroblast cells
- trabeculectomy fistula failure
- corneal fibroblasts
- Dutch Belted rabbits
- ocular inflammation
- uveitis
- glaucoma filtration failure
- Inhibitor
- inhibitor
- inhibit